Indication
For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). High-risk is defined as prostate specific antigen (PSA) doubling time (PSADT) ≤10 months and PSA ≥2 ng/mL.

Medicine details

Medicine name:
enzalutamide (Xtandi)
SMC ID:
SMC2195
Pharmaceutical company
Astellas Pharma Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
07 October 2019
SMC meeting date:
03 September 2019
Patient group submission deadline:
01 July 2019